Ark Therapeutics cancer news

Ark said it was in discussions with employee representatives to reduce headcount in manufacturing, R&D, support staff and non-core early stage research programs. The biotech also said it would place its cancer-induced cachexia candidate Vitor on hold as part of an ongoing restructuring to conserve cash. In December, the company estimated it would have £20 million ($32.2 million) at the end of 2009. ...